Page 19 - MemoriaEHD-Eng

www.ciberehd.org

Additionally, several high-impact publications further show the high

quality of current collaborations, as illustrated by the following few ex-
amples:

• Martínez-Uña M, Varela-Rey M, Cano A, Fernández-Ares L, Beraza N, Aurre-

koetxea I, Martínez-Arranz I, García-Rodríguez JL, Buqué X, Mestre D, Luka
Z, Wagner C, Alonso C, Finnell RH, Lu SC, Martínez-Chantar ML, Aspichue-

ta P, Mato JM. Excess S-adenosylmethionine reroutes phosphatidylethano-

lamine towards phosphatidylcholine and triglyceride synthesis. Hepatology
2013;58:1296-305. (IF 2012: 12.003).

• Guañabens N, Monegal A, Cerdá D, Muxí Á, Gifre L, Peris P, Parés A. Rando-

mized trial comparing monthly ibandronate and weekly alendronate for osteo-

porosis in patients with primary biliary cirrhosis. Hepatology 2013;58:2070-8.
(IF 2012: 12.003).
ñ
• Barbero-Camps E, Fernández A, Martínez L, Fernández-Checa JC, Colell A.

APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and

tau pathology underlying Alzheimer’s disease. Hum Mol Genet 2013;22:3460-
76. (IF 2012: 7.692).

• Uriarte I, Fernandez-Barrena MG, Monte MJ, Latasa MU, Chang HC, Carotti S,

Vespasiani-Gentilucci U, Morini S, Vicente E, Concepcion AR, Medina JF, Marin

JJ, Berasain C, Prieto J, Avila MA. Identification of fibroblast growth factor 15 as
a novel mediator of liver regeneration and its application in the prevention of

post-resection liver failure in mice. Gut 2013;62:899-910. (IF 2012: 10.732).

International networks are also important for Program 3. For instance:

• Vazquez-Chantada M, Gonzalez-Lahera A, Martinez-Arranz I, Garcia-Monzon

C, Regueiro MM, Garcia-Rodriguez JL, Schlangen KA, Mendibil I, Rodriguez-
Ezpeleta N, Lozano JJ, Banasik K, Justesen JM, Joergensen T, Witte DR,

Lauritzen T, Hansen T, Pedersen O, Veyrie N, Clement K, Tordjman J, Tran A,
Le Marchand-Brustel Y, Buque X, Aspichueta P, Echevarria-Uraga JJ, Martin-

Duce A, Caballeria J, Gual P, Castro A, Mato JM, Martinez-Chantar ML, Aran- ü

say AM. Solute carrier family 2 member 1 is involved in the development
of nonalcoholic fatty liver disease. Hepatology 2013;57:505-14. (IF 2012:

12.003).

• Fernandez A, Matias N, Fucho R, Ribas V, Von Montfort C, Nuño N, Baulies

A, Martinez L, Tarrats N, Mari M, Colell A, Morales A, Dubuquoy L, Mathurin
P, Bataller R, Caballeria J, Elena M, Balsinde J, Kaplowitz N, Garcia-Ruiz C,
13
Fernandez-Checa JC. ASMase is required for chronic alcohol induced hepatic 20
üT
endoplasmic reticulum stress and mitochondrial cholesterol loading. J Hepatol OR
2013;59:805-13. (IF 2012: 9.858).
P
RE
• Baares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, Saliba F, L
A
Sauerbruch T, Klammt S, Ockenga J, Pares A, Wendon J, Brnnler T, Kramer NU
N
L, Mathurin P, de la Mata M, Gasbarrini A, Mllhaupt B, Wilmer A, Laleman W, A
Eefsen M, Sen S, Zipprich A, Tenorio T, Pavesi M, Schmidt HH, Mitzner S, Wi- D /
H
lliams R, Arroyo V; RELIEF study group. Extracorporeal albumin dialysis with E
ER
the molecular adsorbent recirculating system in acute-on-chronic liver failure: IB
the RELIEF trial. Hepatology 2013;57:1153-62. (IF 2012: 12.003).
C

19